Veracyte Decipher Prostate test predicts benefit of adding hormone therapy to radiation in Phase III trial analysis
Bitget2026/09/29 12:05- Veracyte flagged new Decipher Prostate test data from a retrospective analysis of the phase III NRG/RTOG 0815 trial.
- Results will be presented at the ASTRO Annual Meeting on Sept. 29, 2026.
- Study found the test identified intermediate-risk patients likely to gain meaningful benefit from adding short-term hormone therapy to radiation.
- Patients with low-risk genomic profiles showed little added benefit, supporting potential treatment de-intensification to avoid hormone-therapy side effects.
- Findings broaden Decipher’s role from risk assessment to treatment selection, reinforcing its strategic value in the intermediate-risk care pathway.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
After acquiring SpotHero, Uber (UBER.US) makes its debut in the parking sector with a parking space reservation feature, initially available in 15 U.S. cities
Uber has launched a brand new parking space reservation feature, which marks its first step in the parking sector following its acquisition of the parking app SpotHero earlier this year.
Arbitrum will welcome a new propAMM
Domestic sales "underperform," PepsiCo (PEP.US) launches mass layoffs of thousands in North America
PepsiCo North America has cut about 1,000 jobs to streamline operations, as beverage sales in the third quarter fell by 2% year-on-year and the full-year profit outlook has been revised downward.
WLFI: Token buyback will be carried out on Aster through a public wallet
Crypto prices
More
